Genomic Health and Cleveland Diagnostics Partner to Develop New Prostate Cancer Tests

Genomic Health and Cleveland Diagnostics Partner to Develop New Prostate Cancer Tests
Genomic Health and Cleveland Diagnostics have entered into a global licensing agreement to develop and commercialize new prostate cancer tests based on the latter company’s IsoPSA technology. The goal is to develop a high-prostate-specific antigen (PSA) reflex test to accurately predict the presence of high-grade cancer — as measured by a Gleason score of 7 or above —

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *